Uncovering the role of oncogenic HER2 variants as drivers of pancreatic cancer.

被引：0
|
作者：
Kanu, Elishama
Sills, Joelle
Shelley, Rebecca
Ginzel, Joshua
Fernandes, Joseph
Agritelley, Ethan
Fletcher, Ash
Borowsky, Alexander D.
Shi, Chanjuan
Cardiff, Robert D.
Nussbaum, Daniel
Allen, Peter J.
Snyder, Joshua
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Duke Univ, Sch Med, Durham, NC USA
[3] Univ Calif Davis, Davis, CA USA
[4] Duke Univ, Med Ctr, Dept Surg, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.772
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：772 / 772
页数：1
相关论文
共 50 条
  • [31] Relative contribution to Her2 protein levels by chromosome 17 aneuploidy and Her2 gene amplification in breast cancer.
    Wang, S
    Saboorian, MH
    Frenkel, E
    Haly, B
    Siddiqui, MT
    Gokaslan, ST
    Ashfaq, R
    MODERN PATHOLOGY, 2001, 14 (01) : 40A - 40A
  • [32] Relative contributions to Her2 protein levels by chromosome 17 aneuploidy and Her2 gene amplification in breast cancer.
    Wang, S
    Saboorian, MH
    Frenkel, E
    Haly, B
    Siddiqui, MT
    Gokaslan, ST
    Ashfaq, R
    LABORATORY INVESTIGATION, 2001, 81 (01) : 40A - 40A
  • [33] In vitro functional analysis of HER2 variants in lung cancers to evaluate their oncogenic activity and predict clinical response to HER2 targeted therapies.
    Offin, Michael
    Olah, Zachary T.
    Sabari, Joshua K.
    Tandon, Nidhi
    Feldman, Daniel
    Abou-Alfa, Ghassain K.
    Lok, Benjamin H.
    Burck, Nitza
    Tarcic, Gabi
    Miron, Ben
    Arcila, Maria E.
    Kris, Mark G.
    Rudin, Charles M.
    Li, Bob T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Relationship between serum HER2 level and histologic HER2 status in patients with advanced/recurrent gastric cancer.
    Sasaki, Takahide
    Fuse, Nozomu
    Kuwata, Takeshi
    Takahashi, Mari
    Asano, Hiromichi
    Kaneko, Kazuhiro
    Doi, Toshihiko
    Yoshino, Takayuki
    Kojima, Takashi
    Ochiai, Atsushi
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [35] Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.
    Bachmeier, Beatrice
    Sperinde, Jeff
    Weidler, Jodi Marie
    Lie, Yolanda
    Chenna, Ahmed
    Winslow, John
    Engel, Jutta
    Schubert-Fritschle, Gabriele
    Sommerhoff, Christian
    Petropoulos, Christos J.
    Bates, Michael Patrick
    Huang, Weidong
    Nerlich, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Lung cancers with rare oncogenic drivers: RET, ROS-1, MET, HER2 and BRAF
    Morin, Clara
    Mazieres, Julien
    BULLETIN DU CANCER, 2025, 112 (03) : 3S117 - 3S126
  • [37] HER2/neu gene amplification and copy numbers of HER2/neu and chromosome 17 assessed by fluorescence in situ hybridization (FISH) are not predictive of outcome in resected pancreatic cancer.
    Krasinskas, AM
    Sharif, S
    Cieply, K
    Potter, D
    Elinoff, B
    Liao, L
    Ramanathan, RK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 337S - 337S
  • [38] Correlation of Wilms' Tumor 1 Isoforms with HER2 and ER-α and its Oncogenic Role in Breast Cancer
    Nasomyon, Tapanawan
    Samphao, Srila
    Sangkhathat, Surasak
    Mahattanobon, Somrit
    Graidist, Potchanapond
    ANTICANCER RESEARCH, 2014, 34 (03) : 1333 - 1342
  • [39] TOP2A mRNA expression in HER2 negative breast cancer.
    Gennari, A.
    Sormani, M.
    Pfeffer, U.
    Morandi, L.
    Mustacchi, G.
    Danesi, R.
    Mirisola, V
    Bruzzi, P.
    CANCER RESEARCH, 2009, 69 (02) : 357S - 357S
  • [40] COMPLETE - Study the ErbB2 (HER2) - positive Breast cancer.
    Arnheim, Katharina
    Aktas, Bahriye
    ONKOLOGIE, 2010, 33 (04):
12345